APRETUDE - PrEP FOR WOMEN, MEN, GAY MEN, TRANSGENDER. PrEP JUST GOT BETTER. WOW
3934
APRETUDE (PREP INJECTION) - PrEP FOR WOMEN, MEN, GAY MEN, TRANSGENDER. PrEP JUST GOT BETTER. WOW
Overview
Injectable PrEP (pre-exposure prophylaxis) has revolutionised HIV prevention by offering a long-acting alternative to daily oral medications. Apretude (cabotegravir), approved by the FDA in the USA since 2021 and by Health Canada in May 2024, marks a significant advancement in this field. Unlike daily oral PrEP that requires consistent adherence, Apretude is administered every two months, making it an ideal choice for individuals who may find it challenging to stick to a daily regimen. This injectable form simplifies the prevention process and increases efficacy and user satisfaction.
Apretude's availability represents a promising step forward in the global effort to reduce HIV transmission. By providing a more convenient and long-lasting option, it addresses a critical gap in HIV prevention strategies. The approval of Apretude in both the USA and Canada reflects the growing recognition of the need for diverse prevention tools to cater to different lifestyles and preferences. As more people gain access to this innovative medication, the fight against HIV becomes more robust, offering hope for a future with significantly reduced rates of HIV transmission.
Contact us at info.bkk@pulse-clinic.com or chat on your preferred platform:
+66 65 237 1936 
@PULSEClinic 
PulseClinic
What is Apretude?
Apretude is an injectable form of cabotegravir, a medication specifically designed to prevent HIV infection. Unlike traditional PrEP medications, which require daily oral intake, Apretude is administered via injection in the buttock every two months. This long-acting injectable option provides a convenient and effective method for individuals at risk of HIV, reducing the burden associated with taking pills daily.
In short, APRETUDE (cabotegravir) is a long-acting injectable medication approved for HIV prevention. Unlike traditional oral PrEP, which requires daily doses, APRETUDE is administered once every two months, offering a more convenient and effective solution.
The Benefits of Apretude
- Improved Adherence: One of the advantages of Apretude is its dosing schedule. With only six injections per year (after the initial dosing), it is much easier for individuals to adhere to their HIV prevention regimen compared to the daily pill burden of traditional PrEP.
- Efficacy: Clinical trials have demonstrated that Apretude effectively prevents HIV infection. Studies show superior efficacy compared to daily oral PrEP, providing robust protection against the virus. This may be attributed to the reduced adherence requirements associated with Apretude.
- Convenience: For many people, remembering to take a daily pill can be challenging. Apretude's bimonthly injections offer a convenient alternative, making it easier for individuals to maintain consistent protection.
- Choice: Introducing an alternative to daily oral PrEP empowers patients by providing them with options and enhancing their autonomy in managing their HIV prevention regimen.
Efficacy of Apretude for all populations
Based on the research study
| Injectable PrEP Apretude Efficacy in Different Populations | |||||
| Route or Sex | Straight Men | Straight Women | Gay and Bisexuals | TransWomem | TransMen |
| Oral Sex | more than 99% | more than 99% | more than 99% | more than 99% | more than 99% |
| Anal Sex | more than 99% | more than 99% | more than 99% | more than 99% | more than 99% |
| Vaginal Sex | more than 99% | more than 99% | more than 99% | more than 99% | more than 99% |
SUPERIOR HIV PROTECTION VS TRUVADA
1. STUDY IN CISGENDER MEN AND TRANSGENDER WOMEN
Significantly more people stayed HIV-negative on APRETUDE vs TRUVADA during the study.
69% reduction in the risk of acquiring HIV-1 with APRETUDE (0.37/100 person-years) vs TRUVADA (1.22/100 person-years)
2. STUDY IN CISGENDER WOMEN
Significantly more women stayed HIV-negative on APRETUDE vs TRUVADA during the study.
90% reduction in the risk of acquiring HIV-1 with APRETUDE (0.15/100 person-years) vs TRUVADA (1.85/100 person-years)
Dosing schedule
Based on individual needs, doctors may begin treatment with daily 30 mg tablets of cabotegravir for a month before transitioning to the injectable form of Apretude to assess tolerance. Alternatively, the doctor may decide to start directly with the Apretude injection, bypassing the need for oral pills.
Initially, patients are given Apretude once every month for the first two months, after which it is administered bi-monthly. Please consult your physician today to discuss if Apretude is the right choice for you.
| How to use Apretude 1 | How to use Apretude 2 | |||
| Month 1 | 1 inj starter dose 1 | Month 1 | Daily starter pills (30 days) | |
| Month 2 | 1 inj starter dose 2 | Month 2 | 1 inj (day 30 or within 3 days) | |
| Month 3 | - | Month 3 | - | |
| Month 4 | 1 inj | Month 4 | 1 inj | |
| Month 5 | - | Month 5 | - | |
| Month 6 | 1 inj | Month 6 | 1 inj | |
| Month 7 | - | Month 7 | - | |
| Month 8 | 1 inj | Month 8 | 1 inj | |
| Month 9 | - | Month 9 | - | |
| Month 10 | 1 inj | Month 10 | 1 inj | |
| Month 11 | - | Month 11 | - | |
| Month 12 | 1 inj | Month 12 | 1 inj | |
How much does Apretude cost?
In Thailand, VIIV Healthcare has set the price for Apretude, the new injectable PrEP, at 19500THB/dose every 2 months.
Pre-Order Apretude At PULSE Clinic (Thailand)
Contact us at info.bkk@pulse-clinic.com or chat on your preferred platform:
+66 65 237 1936 @PULSEClinic PulseClinic
Do insurance companies cover Apretude?
VIIV Healthcare, the manufacturer of Apretude, is currently negotiating with private insurance companies to establish pricing and secure comprehensive coverage for this medication. This process may take up to one year.
Can I fly to Thailand to get Apretude as a foreigner?
Yes, definitely. PULSE CLINIC has 11 branches in Thailand, consisting of 5 branches in Bangkok, 2 branches in Pattaya, 2 branches on Phuket Island, 1 branch on Samui Island, and 1 branch in Chiang Mai. You can enjoy your weekend or holiday, it doesn't matter if you want to party and play; PULSE CLINICs are open daily and prescribe PrEP to everyone who has a a prescription or lab test result from the last 3 months.
Side effects and disadvantages
Apretude, like any medication, can come with its share of side effects. Common ones include headaches, diarrhea, and hot flashes. Additionally, individuals may experience pain, redness, and swelling at the injection site.
One drawback of Apretude is its mode of administration. Unlike oral medications that can be taken at home, Apretude requires administration by a nurse or doctor.
Moreover, for individuals with needle phobia, the requirement for injection can be particularly daunting, potentially favoring the use of daily oral pills instead. It's essential to discuss these considerations with your healthcare provider to determine the most suitable HIV prevention option for you.
Coming Soon!
The approval of Apretude marks a significant milestone in HIV prevention, offering a new, convenient, and effective option for individuals at risk. By reducing the frequency of dosing and enhancing adherence, Apretude empowers patients with greater autonomy and flexibility in their HIV prevention regimen. Stay tuned for the availability of Apretude at PULSE Clinic & Pharmacy, or speak to one of our healthcare providers today!
Add us on Line and stay in touch.
Sources:
- High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia. Journal of Community Health (2023)
- Determinants of Pre-exposure Prophylaxis (PrEP) Implementation in Transgender Populations: A Qualitative Scoping Review (2022)
- Gay, Bisexual, and Other Men Who Have Sex With Men Who Are Not on Oral PrEP may be Less Interested in Available Injectable Products than in Oral PrEP: Examining Individual-Level Determinants of Interest and Barriers Across Products (2022)
Add us on Line and stay in touch.
Loading...
Clinic Locations
Loading...
